Nouscom • Re-defining innovation
Nouscom is a clinical-stage immuno-oncology company developing next-generation viral vector cancer vaccines based on neoantigens. Founded in 2015, the company's proprietary platform uses recombinant adenoviruses derived from non-human great apes (GAd) and MVA to generate potent anti-tumor immune responses, enabling both off-the-shelf and personalized cancer immunotherapies. Nouscom is headquartered in Basel, Switzerland, with research operations in Rome, Italy.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountMar 2024
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
